Table 4.

Grade 3 or 4 adverse events

	All patients			High-dose dexamethasone patients
	thal/dex (n = 183), n (%)	len/dex (n = 228), n (%)	P	thal/dex (n = 72), n (%)	len/dex (n = 72), n (%)	P
Treatment-related deaths	1 (0.5)	3 (1.3)	.632	1 (1.4)	2 (2.8)	> .999
At least one grade 3 or 4 adverse event	100 (54.6)	131 (57.5)	.568	44 (61.1)	51 (70.8)	.218
Hematologic
Anemia	0 (0)	10 (4.4)	.003	0 (0)	3 (4.2)	.245
Thrombocytopenia	0 (0)	11 (4.8)	.002	0 (0)	3 (4.2)	.245
Neutropenia	1 (0.6)	32 (14.0)	< .001	0 (0)	10 (13.9)	.001
Extrahematologic
Peripheral neuropathy	19 (10.4)	2 (0.9)	< .001	3 (4.2)	0 (0)	.245
Fatigue	13 (7.1)	23 (10.1)	.288	5 (6.9)	10 (13.9)	.275
Gastrointestinal toxicity	12 (6.6)	14 (6.1)	.863	5 (6.9)	7 (9.7)	.764
Constipation	9 (4.9)	0 (0)	.001	4 (5.6)	0 (0)	.120
Diarrhea	0 (0)	8 (3.5)	.01	0 (0)	3 (4.2)	.245
Venous thromboembolism	28 (15.3)	21 (9.2)	.058	14 (19.4)	8 (11.1)	.165
DVT	21* (11.5)	16 (7.0)	.117	9* (12.5)	6 (8.3)	.413
Pulmonary embolism	7 (3.8)	5 (2.2)	.385	5 (6.9)	2 (2.8)	.441
Dermatologic	12 (6.6)†	21 (9.7)‡	.258	6 (8.3)	5 (6.9)‡	> .999
Infections	15 (8.2)	30 (13.1)	.109	6 (8.3)	10 (13.8)	.289
Pneumonia	5 (2.7)	16 (7.0)	.070	1 (1.4)	8 (11.1)	.033
Sepsis	2 (1.1)	4 (1.8)	.696	1 (1.4)	0 (0)	> .999
Cardiovascular	10 (5.5)	10 (4.4)	.614	5 (6.9)	5 (6.9)	> .999
Transaminase increase	0 (0)	7 (3.1)	.019	0 (0)	4 (5.6)	.120
Myopathy	4 (2.2)	1 (0.4)	.177	2 (2.8)	1 (1.4)	> .999

^*One plus hemorrhage.

^†One Steven-Johnson syndrome and 1 toxic epidermal necrolysis.

^‡One Stevens-Johnson syndrome.